Mangoceuticals(MGRX) - 2023 Q1 - Quarterly Report

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the fiscal quarter ended March 31, 2023 Washington, D.C. 20549 FORM 10-Q (Mark One) FOR THE TRANSITION PERIOD FROM _____________ TO _____________ Commission File Number 001-41615 Mangoceuticals, Inc. (Exact name of registrant as specified in its charter) incorporation or organization) 15110 N. Dallas Parkway, Suite 600 Dallas, Texas 75248 (Address of principal execut ...